U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H6N4O3
Molecular Weight 182.1368
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 1-METHYLURIC ACID

SMILES

CN1C(=O)NC2=C(NC(=O)N2)C1=O

InChI

InChIKey=QFDRTQONISXGJA-UHFFFAOYSA-N
InChI=1S/C6H6N4O3/c1-10-4(11)2-3(9-6(10)13)8-5(12)7-2/h1H3,(H,9,13)(H2,7,8,12)

HIDE SMILES / InChI

Molecular Formula C6H6N4O3
Molecular Weight 182.1368
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

PubMed

PubMed

TitleDatePubMed
Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers.
2009-08
Two distinct pathways for metabolism of theophylline and caffeine are coexpressed in Pseudomonas putida CBB5.
2009-07
Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
2009-05
Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?
2009-04
Relaxing and contracting effects of theophylline's metabolites on the rabbit upper gastrointestinal tract.
2008-10
Anti-inflammatory effect of theophylline in rats and its involvement of the glucocorticoid-glucocorticoid receptor system.
2008-04
Theophylline and its metabolites produce a stimulating cholinergic effect on the small intestine and a nonadrenergic noncholinergic relaxing effect on the colon: a comparative study in the rabbit intestine.
2007-12
In vitro antioxidant activity of coffee compounds and their metabolites.
2007-08-22
Lack of effect of aciclovir on metabolism of theophylline and expression of hepatic cytochrome P450 1A2 in rats.
2007-03
In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
2007-02
Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay.
2007-02
Effect of a newly developed ketolide antibiotic, telithromycin, on metabolism of theophylline and expression of cytochrome P450 in rats.
2006-05-30
Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
2006-05
[Determination of the activity of cytochrome P-450 CYP2A6 by HPLC method with caffeine as metabolizing probe].
2006-03
An unusual patient with kidney stones composed of 1-methyluric acid.
2006-02
Simultaneous high performance liquid chromatographic separation of purines, pyrimidines, N-acetylated amino acids, and dicarboxylic acids for the chemical diagnosis of inborn errors of metabolism.
2005-11
Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice.
2005-07
Inhibition of theophylline metabolism by suplatast and its metabolites in rats.
2005-06
Improved HPLC assay for measuring serum vitamin C with 1-methyluric acid used as an electrochemically active internal standard.
2005-06
Measurement of caffeine and five of the major metabolites in urine by high-performance liquid chromatography/tandem mass spectrometry.
2005-03
Separation, pre-concentration, and HPLC analysis of methylxanthines in urine samples.
2004-10
Catabolism of caffeine in plants and microorganisms.
2004-05-01
Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
2004-03
Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study.
2004
Cytochrome P450 1A2 (CYP1A2) activity, mammographic density, and oxidative stress: a cross-sectional study.
2004
Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.
2003-02
Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation.
2002-12
Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
2002-08
Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.
2001-11
[The acetylator polymorphism in a Khmer population: clinical consequences].
2001-10-27
Dose dependent pharmacokinetics of theophylline: Michaelis-Menten parameters for its major metabolic pathways.
2001-09-14
Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects.
2001-09
Use of novel solid-phase extraction sorbent materials for high-performance liquid chromatography quantitation of caffeine metabolism products methylxanthines and methyluric acids in samples of biological origin.
2001-08-15
The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans.
2001-08
Caffeine metabolism before and after liver transplantation.
2001-02
Xanthine oxidase activity and blood glutathione redox ratio in infants and children with septic shock syndrome.
2001-01
Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis.
2001-01
Developmental changes in urinary elimination of theophylline and its metabolites in pediatric patients.
1999-01
Neurotoxic convulsions induced by theophylline and its metabolites in mice.
1996-06
Human N-acetylation genotype determination with urinary caffeine metabolites.
1990-04
Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease.
1988-09
Reversed-phase liquid chromatographic investigation of UV-absorbing low-molecular-weight compounds in saliva.
1982-12-10
Effects of allopurinol on theophylline metabolism and clearance.
1979-11
Patents
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:17:07 GMT 2025
Edited
by admin
on Mon Mar 31 19:17:07 GMT 2025
Record UNII
2WS4HQ639J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
1-METHYL-2,6,8-TRIHYDROXYPURINE
Preferred Name English
1-METHYLURIC ACID
Systematic Name English
1-METHYL-7,9-DIHYDRO-3H-PURINE-2,6,8-TRIONE
Systematic Name English
Code System Code Type Description
CAS
708-79-2
Created by admin on Mon Mar 31 19:17:07 GMT 2025 , Edited by admin on Mon Mar 31 19:17:07 GMT 2025
PRIMARY
MESH
C030530
Created by admin on Mon Mar 31 19:17:07 GMT 2025 , Edited by admin on Mon Mar 31 19:17:07 GMT 2025
PRIMARY
PUBCHEM
69726
Created by admin on Mon Mar 31 19:17:07 GMT 2025 , Edited by admin on Mon Mar 31 19:17:07 GMT 2025
PRIMARY
ECHA (EC/EINECS)
211-905-7
Created by admin on Mon Mar 31 19:17:07 GMT 2025 , Edited by admin on Mon Mar 31 19:17:07 GMT 2025
PRIMARY
EPA CompTox
DTXSID70221063
Created by admin on Mon Mar 31 19:17:07 GMT 2025 , Edited by admin on Mon Mar 31 19:17:07 GMT 2025
PRIMARY
FDA UNII
2WS4HQ639J
Created by admin on Mon Mar 31 19:17:07 GMT 2025 , Edited by admin on Mon Mar 31 19:17:07 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> METABOLITE
PARENT -> METABOLITE INACTIVE